Low-dose rituximab for posttransplant recurrent membranous nephropathy: Letter to the editor

American Journal of Transplantation

Volumn 10, Issue 5, 2010, Pages 1336-

  Cravedi, P ^a   Ruggenenti, P ^a   Remuzzi, G ^a  

^a MARIO NEGRI INST PHARMACOL RES   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

COST CONTROL; DRUG COST; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG TOLERABILITY; GRAFT RECIPIENT; HISTOPLASMOSIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LETTER; LOW DRUG DOSE; MEMBRANOUS GLOMERULONEPHRITIS; PNEUMONIA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROTEINURIA;

ADULT; ANTIBODIES, MONOCLONAL; FEMALE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; MALE; MIDDLE AGED; RECURRENCE;

EID: 77951237608     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2010.03029.x     Document Type: Letter

References (5)

1. El-Zoghby ZM, Grande JP, Fraile MG et al. Recurrent idiopathic membranous nephropathy: Early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies. Am J Transplant 2009 9 : 2800 2807.
2. Ruggenenti P, Chiurchiu C, Brusegan V et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 2003 14 : 1851 1857 (Pubitemid 36750480)
3. Carson KR, Evens AM, Richey EA et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: A report of 57 cases from the research on adverse drug events and reports project. Blood 2009 113 : 4834 4840.
4. Ruggenenti P, Cravedi P, Remuzzi G. Rituximab for membranous nephropathy and immune disease: Less might be enough. Nat Clin Pract Nephrol 2009 5 : 76 77.
5. Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2007 2 : 932 937.